Zatosetron

In the world of Zatosetron, we can find a wide variety of elements that allow us to explore and deepen their meaning. From its origins to the present, Zatosetron has played a fundamental role in people's lives, significantly impacting multiple aspects. Throughout history, Zatosetron has been the subject of study, debate and controversy, which has contributed to the enrichment of knowledge on this topic. In this article, we will delve into the world of Zatosetron to understand its importance, evolution and relevance in today's society.

Zatosetron
Clinical data
ATC code
  • none
Identifiers
  • 5-chloro-2,2-dimethyl-N-(8-methyl-8-azabicyclooct-3-yl)-2,3-dihydro-1-benzofuran-7-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H25ClN2O2
Molar mass348.87 g·mol−1
3D model (JSmol)
  • CC1(Cc2cc(cc(c2O1)C(=O)N3C4CC(C3)N4C)Cl)C
  • InChI=1S/C19H25ClN2O2/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23)/t13-,14+,15-
  • Key:SPKBYQZELVEOLL-QDMKHBRRSA-N
 ☒NcheckY (what is this?)  (verify)

Zatosetron (LY-277,359) is a drug which acts as an antagonist at the 5HT3 receptor It is orally active and has a long duration of action, producing antinauseant effects but without stimulating the rate of gastrointestinal transport. It is also an effective anxiolytic in both animal studies and human trials, although with some side effects at higher doses.

See also

References

  1. ^ Cohen ML, Bloomquist W, Gidda JS, Lacefield W (July 1990). "LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity". The Journal of Pharmacology and Experimental Therapeutics. 254 (1): 350–5. PMID 2366187.
  2. ^ Robertson DW, Lacefield WB, Bloomquist W, Pfeifer W, Simon RL, Cohen ML (January 1992). "Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships". Journal of Medicinal Chemistry. 35 (2): 310–9. doi:10.1021/jm00080a016. PMID 1732548.
  3. ^ Schwartz SM, Goldberg MJ, Gidda JS, Cerimele BJ (March 1994). "Effect of zatosetron on ipecac-induced emesis in dogs and healthy men". Journal of Clinical Pharmacology. 34 (3): 250–4. doi:10.1002/j.1552-4604.1994.tb03994.x. PMID 7517409. S2CID 23486859.
  4. ^ Smith WT, Londborg PD, Blomgren SL, Tollefson GD, Sayler ME (April 1999). "Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety". Journal of Clinical Psychopharmacology. 19 (2): 125–31. doi:10.1097/00004714-199904000-00006. PMID 10211913.
  5. ^ Williams PD, Calligaro DO, Colbert WE, Helton DR, Shetler T, Turk JA, Jordan WH (March 1991). "General pharmacology of a new potent 5-hydroxytryptamine antagonist". Arzneimittel-Forschung. 41 (3): 189–95. PMID 1867653.
  6. ^ Bendele A, Means J, Shoufler J, Schmalz C, Hanasono G, Symanowski J, Adams E (February 1995). "Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys". Drug and Chemical Toxicology. 18 (1): 61–82. doi:10.3109/01480549509017858. PMID 7768200.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia